NCT02616770 - Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Asthma

Interventions

DRUG

S1226 (4%)

3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.

DRUG

Saline (for 4%)

3ml saline nebulized, with Medical Air, for 2 minutes as a single dose

DRUG

S1226(8%)

3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.

DRUG

Saline (for 8%)

3ml saline nebulized, with Medical Air, for 2 minutes as a single dose

DRUG

S1226(12%)

3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.

DRUG

Saline (for 12%)

3ml saline nebulized with Medical Air for 2 minutes as a single dose

All Listed Sponsors

lead

SolAeroMed Inc.

INDUSTRY